Dr. Kamaljit Kaur's lab at Chapman University focuses on improving chemotherapy for triple-negative breast cancer (TNBC) using specially designed peptide-drug conjugates. These conjugates are engineered to specifically target cancer cells, aiming to enhance drug effectiveness while minimizing harmful side effects on normal tissues. The lab is working on innovative approaches that could revolutionize cancer treatment and offer better outcomes for patients.

Dr. Sun Yang's lab at Chapman University focuses on developing new treatments for cutaneous melanoma, the most aggressive type of skin cancer. The lab is particularly interested in small molecules that can selectively inhibit an enzyme called neuronal nitric oxide synthase (nNOS), which plays a critical role in melanoma progression and immune system evasion. By designing and testing novel nNOS inhibitors, the lab aims to improve treatment outcomes, especially for patients who do not respond to current therapies.

Dr. Jennifer E Totonchy's lab at Chapman University studies the Kaposi sarcoma-associated herpesvirus (KSHV), which can cause serious health issues, especially in individuals with weakened immune systems, such as those with HIV. The lab explores how KSHV infects key immune cells in the tonsils, particularly focusing on plasma cells. By understanding early KSHV infection events, they aim to uncover new approaches to combat this virus and its associated diseases.